NextCell Pharma
1.28 SEK -0.78%Be the first to follow this company
NextCell Pharma operates in the healthcare sector. Today, development is carried out of stem cell products mainly used in the treatment of autoimmune diabetes and for kidney transplants. A significant part of the work consists of stem cell research where the company develops drug candidates that should enable and increase the acceptance of organ transplants. In addition, the company has a stem cell bank. The company was established in 2014 and is based in Huddinge.
Revenue
10.11M
EBIT %
-405.54 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
NXTCL
Daily low / high price
1.27 / 1.395
SEK
Market cap
44.01M SEK
Turnover
73.21K SEK
Volume
56K
Financial calendar
Extraordinary general meeting
2024-05-27
Interim report
2024-07-25
Annual report
2024-10-24
General meeting
2024-11-28
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Diamyd Medical AB | 12.5 % | 12.5 % |
Avanza Pension | 10.3 % | 10.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
NextCell Pharma AB: NextCell Pharma offentliggör Delårsrapport 2 för 2023/2024
Kallelse till extra bolagsstämma i NextCell Pharma AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools